Literature DB >> 25983111

The function of ultra-large von Willebrand factor multimers in high shear flow controlled by ADAMTS13.

A J Reininger1.   

Abstract

The paradigm that platelet aggregation, which contributes to bleeding arrest and also to thrombovascular disorders, initiates after signaling-induced platelet activation has been refuted in past recent years. Platelets can form aggregates independently of activation when soluble von Willebrand factor (VWF) is present and the shear rate exceeds a certain threshold where active A1 domains become exposed in soluble VWF multimers and can bind to platelet glycoprotein Ib. Subsequently - fostering each other - VWF can self-assemble into large nets combining with platelets into large conglomerates, which are entirely reversible when they enter a flow region with shear rates below the threshold. In addition the threshold changes from approximately 20 000 s⁻¹ in wall parallel flow to approximately 10 000 s⁻¹ in stagnation point flow. VWF containing ultra-large multimers - as when just released from endothelial storage sites - has been shown to have the highest binding potential to platelets and to each other, thus facilitating rapid platelet accrual to sites of vessel injury and exposed subendothelial structures, i.e. collagen. The VWF nets as well as the platelet-VWF conglomerates are controlled by the cleaving protease ADAMTS13 within minutes under high shear flow. Therewith the hemostatic potential is delivered where needed and the thrombogenic potential is highly controlled twofold: by flow and enzymatic proteolytic cleavage.

Entities:  

Keywords:  ADAMTS13; Von Willebrand factor; shear stress

Mesh:

Substances:

Year:  2015        PMID: 25983111     DOI: 10.5482/HAMO-14-12-0077

Source DB:  PubMed          Journal:  Hamostaseologie        ISSN: 0720-9355            Impact factor:   1.778


  6 in total

1.  New therapies for von Willebrand disease.

Authors:  Pier Mannuccio Mannucci
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

2.  Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease.

Authors:  Joan C Gill; Giancarlo Castaman; Jerzy Windyga; Peter Kouides; Margaret Ragni; Frank W G Leebeek; Ortrun Obermann-Slupetzky; Miranda Chapman; Sandor Fritsch; Borislava G Pavlova; Isabella Presch; Bruce Ewenstein
Journal:  Blood       Date:  2015-08-03       Impact factor: 22.113

3.  New therapies for von Willebrand disease.

Authors:  Pier Mannuccio Mannucci
Journal:  Blood Adv       Date:  2019-11-12

4.  Levels and activities of von Willebrand factor and metalloproteinase with thrombospondin type-1 motif, number 13 in inflammatory bowel diseases.

Authors:  Dorota Cibor; Danuta Owczarek; Saulius Butenas; Kinga Salapa; Tomasz Mach; Anetta Undas
Journal:  World J Gastroenterol       Date:  2017-07-14       Impact factor: 5.742

5.  vWF/ADAMTS13 is associated with on-aspirin residual platelet reactivity and clinical outcome in patients with stable coronary artery disease.

Authors:  Ellen M K Warlo; Alf-Åge R Pettersen; Harald Arnesen; Ingebjørg Seljeflot
Journal:  Thromb J       Date:  2017-11-22

6.  Phase 3 study of recombinant von Willebrand factor in patients with severe von Willebrand disease who are undergoing elective surgery.

Authors:  F Peyvandi; A Mamaev; J-D Wang; O Stasyshyn; M Timofeeva; N Curry; A R Cid; T T Yee; K Kavakli; G Castaman; A Sytkowski
Journal:  J Thromb Haemost       Date:  2018-12-20       Impact factor: 5.824

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.